By in

Sativa begins cannabinoid research with King’s College London

Press Release                                                                                                                      2nd April 2019

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.  Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

Sativa Investments PLC 

 (“Sativa” or “the Company”)

Sativa begins cannabinoid research with King’s College London 

Sativa Investments PLC (NEX: SATI), the UK’s first medicinal cannabis investment vehicle,has entered into a research agreement with King’s College London (“the College”) to research the impact of cannabinoids on inflammation and respiratory diseases. 

The research will be led by Professor Clive Page OBE PhD Professor of Pharmacology at King’s College London.  Professor Page is a world authority on the pharmacology of inflammation and respiratory disease, having published over 250 scientific papers.  He is a Fellow of the Royal Society of Biology and the British Pharmacological Society, and was awarded an OBE in 2017 for his “Services to Pharmacology.” 

Sativa, which has a medicinal cannabis grower’s licence in process through the Home Office Drugs Licensing and Compliance Unit, will, subject to regulatory consent, supply the university, to order, with specific strains of cannabis plants that contain various combinations of the spectrum of at least 113 known cannabinoids.  The Company is able to provide this service through a combination of its commercial agreement with investee business Canada-based Veritas Pharma Inc., which specialises in identifying the optimum cultivation of various strains, and Sativa’s own on-site and highly successful testing facility, PhytoVista Laboratories, that has already undertaken over 1,000 forensic tests relating to a wide variety of cannabinoids, and is accredited and recommended by the UK’s Cannabis Trades Association (“CTA”). 

Geremy Thomas, founder and Chief Executive Officer of Sativa Investments, said: “With the UK catching up fast in terms of recognising the benefits of medicinal cannabis, in-country research from the globally-recognised King’s College London will assist the medical profession, Government and Regulators in their deliberations. 

“As the UK’s first medicinal cannabis investment vehicle, Sativa remains at the forefront of this fast-developing sector, which effectively mirrors what has been happening in North America since medicinal cannabis was first legalised in Canada in 2001, more than 17 years ago,”

The Directors of the Company accept responsibility for the contents of this announcement.

–  Ends –

For further information please contact:

Geremy Thomas

Founder & Chief Executive Officer

Sativa Investments PLC

+44 (0) 20 7971 1255

enquiries@sativainvestments.co.uk

 

NEX Exchange Corporate Adviser

Guy Miller and Lucy Williams

Peterhouse Capital Limited 

+44 (0) 20 7469 0930

gm@peterhousecap.com

 

Financial PR and IR

Abchurch Communications

Julian Bosdet / Dylan Mark /

Alejandra Campuzano

Abchurch Switchboard

SativaInvestments@abchurch-group.com

Joseph Colliver

Chief Financial Officer

Sativa Investments PLC

+44 (0) 20 7971 1255

enquiries@sativainvestments.co.uk

+44 (0) 20 7469 4633 / 4634

 

 

+44 (0) 20 7469 4630

www.abchurch-group.com

Notes to Editors

Sativa invests in well-placed ventures within the dynamic regulatory environment of the Medicinal Cannabis sector. The Company’s pan-European, end-to-end, seed-to-consumer investment strategy focuses on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily permitted.  Sativa has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment. 

The Company’s equity interest in an investment may range from a minority position, to a controlling interest, or to 100 per cent ownership.  The ventures that Sativa acquires can either be public or private.

Sativa Investments has already made six investments to date, these being Canada-based and dual-listed emerging pharmaceutical company,Veritas Pharma Inc. (“Veritas Pharma” or “Veritas”), CSE-listed Toronto-based Pharma-Tech company Rapid Dose Therapeutics Inc. (“RDT”), which owns the patent-pending proprietary QuickStrip™ technology, UK-based CBD products provider George Botanicals Ltd (of which Sativa has 100 per cent ownership), PhytoVista Laboratories (of which Sativa also has 100 per cent ownership), a UK testing laboratory meeting the need for regulatory and batch testing of products such as CBD oil, a joint venture withGermany’s Lexamed GmbH, and an option ona 7.53-acre development site in Wiltshire with the potential to build a glasshouse for growing raw cannabis for medicinal and CBD use. 

Sativa is also focussed on researching and developing medicinal cannabis products by funding university research grants of medicinal cannabis through its Sativa Foundation.

The Company’s Board and Medicinal Cannabis Advisory Board have a combined 60 years’ industry experience, with significant pharmaceutical strength and experience and extensive contacts in the industry, which includes pharmacologist Sir Alasdair Breckenridge, who liaises with the Home Office and the Medicines and Healthcare products Regulatory Agency, which he has chaired, for the legalisation of medicinal cannabis in the UK Their extensive skills range from capital fund raisings, medical research, and start-ups, to pharmaceutical development. 

For more information on Sativa Investments, please visit: www.sativagroup.co.uk